These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14684676)

  • 1. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?
    Laverman GD; Remuzzi G; Ruggenenti P
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S64-70. PubMed ID: 14684676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
    MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
    Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist.
    Berl T
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S71-6. PubMed ID: 14684677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
    Kalantarinia K; Okusa MD
    Curr Diab Rep; 2006 Feb; 6(1):8-16. PubMed ID: 16522275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
    Deferrari G; Ravera M; Deferrari L; Vettoretti S; Ratto E; Parodi D
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S224-9. PubMed ID: 12466318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R; Tonolo G
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
    Weinberg MS; Kaperonis N; Bakris GL
    Curr Hypertens Rep; 2003 Oct; 5(5):418-25. PubMed ID: 12948435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials.
    Stojiljkovic L; Behnia R
    Curr Pharm Des; 2007; 13(13):1335-45. PubMed ID: 17506719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.